KT-474 Demonstrates Efficacy and Promise in Atopic Dermatitis and Hidradenitis Suppurativa Study
Jared Gollob, MD, Chief Medical Officer of Kymera Therapeutics, spoke with Dermatology Times to discuss these trial results.